4 European Projects Found
Searched on 125080 European Projects
FINISHED
Endoplasmic Reticulum Stress in Health and Disease (TRAIN-ERS)
Start date: Oct 1, 2015, End date: Sep 30, 2019,
Endoplasmic reticulum (ER) stress is emerging as a common feature in the pathology of numerous diseases including cancer, neurodegenerative disorders, metabolic syndromes and inflammatory diseases. Thus ER stress represents a potential therapeutic intervention point to be exploited to develop novel therapies, diagnostic tools and markers for these diseases. However, exploitation is hampered by the ...
Read Project
12
Partners Participants
FINISHED
Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine (MEL-PLEX)
Start date: Dec 1, 2014, End date: Nov 30, 2018,
Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous and chemotherapy resistant cancers, such as malignant melanoma. This can only be achieved by industry-academia collaborations in newly emerging, innovative research disciplines such as translational cancer systems biology and systems medicine. These disciplines ...
Read Project
11
Partners Participants
FINISHED
Drug Disease Model Resources (DDMORE)
Start date: Mar 1, 2011, End date: Aug 31, 2016,
Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Read Project
28
Partners Participants
FINISHED
Apoptosis Modelling for Treatment Decisions in Colorectal Cancer (APO-DECIDE)
Start date: Nov 1, 2012, End date: Oct 31, 2014,
"With the arrival of new colorectal cancer (CRC) therapeutics targeting specific cell signalling pathways, such as anti-EGFR therapy, personalised cancer treatment is at the door step of clinical practise. This progress in drug development contrasts strikingly with current clinical practice, where decision making depends largely on clinical factors such as tumour staging and age of patient, with t ...
Read Project
